Consequently, PCa patients are typically categorized into risk strata predicated on the prostate-specific antigen (PSA) concentration, clinical T classification, and biopsy-derived Gleason score (GS) [5,6]. This evidence concerns the gene KLK3 and posterior cortical atrophy.